ACT TADALAFIL DIN 02428628
Health Canada record
| Active ingredient(s) | TADALAFIL 2.5 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | G04BE08 TADALAFIL |
| Original market date | 12-Jul-2016 |
| Current status date | 30-Jul-2025 |
| Source | Health Canada DPD |
Establishment licence of the holder
Teva Canada Limited — licence 101810, currently licensed, last inspection rating C (2025-03-04).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing TADALAFIL
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02422115 | APO-TADALAFIL | APOTEX INC | Tablet | TADALAFIL 20 MG | Marketed |
| 02422085 | APO-TADALAFIL | APOTEX INC | Tablet | TADALAFIL 2.5 MG | Marketed |
| 02422093 | APO-TADALAFIL | APOTEX INC | Tablet | TADALAFIL 5 MG | Marketed |
| 02422107 | APO-TADALAFIL | APOTEX INC | Tablet | TADALAFIL 10 MG | Marketed |
| 02421933 | APO-TADALAFIL PAH | APOTEX INC | Tablet | TADALAFIL 20 MG | Marketed |
| 02435942 | AURO-TADALAFIL | AURO PHARMA INC | Tablet | TADALAFIL 20 MG | Marketed |
| 02435934 | AURO-TADALAFIL | AURO PHARMA INC | Tablet | TADALAFIL 10 MG | Marketed |
| 02435926 | AURO-TADALAFIL | AURO PHARMA INC | Tablet | TADALAFIL 5 MG | Marketed |
| 02435896 | AURO-TADALAFIL | AURO PHARMA INC | Tablet | TADALAFIL 2.5 MG | Marketed |
| 02248088 | CIALIS | ELI LILLY CANADA INC | Tablet | TADALAFIL 10 MG | Marketed |
| 02296888 | CIALIS | ELI LILLY CANADA INC | Tablet | TADALAFIL 2.5 MG | Marketed |
| 02296896 | CIALIS | ELI LILLY CANADA INC | Tablet | TADALAFIL 5 MG | Marketed |
| 02248089 | CIALIS | ELI LILLY CANADA INC | Tablet | TADALAFIL 20 MG | Marketed |
| 02448653 | IPG-TADALAFIL | MARCAN PHARMACEUTICALS INC | Tablet | TADALAFIL 2.5 MG | Approved |
| 02448661 | IPG-TADALAFIL | MARCAN PHARMACEUTICALS INC | Tablet | TADALAFIL 5 MG | Approved |
| 02448688 | IPG-TADALAFIL | MARCAN PHARMACEUTICALS INC | Tablet | TADALAFIL 10 MG | Approved |
| 02448696 | IPG-TADALAFIL | MARCAN PHARMACEUTICALS INC | Tablet | TADALAFIL 20 MG | Approved |
| 02451832 | JAMP-TADALAFIL | JAMP PHARMA CORPORATION | Tablet | TADALAFIL 5 MG | Marketed |
| 02451840 | JAMP-TADALAFIL | JAMP PHARMA CORPORATION | Tablet | TADALAFIL 10 MG | Marketed |
| 02451859 | JAMP-TADALAFIL | JAMP PHARMA CORPORATION | Tablet | TADALAFIL 20 MG | Marketed |
| 02452251 | MAR-TADALAFIL | MARCAN PHARMACEUTICALS INC | Tablet | TADALAFIL 10 MG | Marketed |
| 02452278 | MAR-TADALAFIL | MARCAN PHARMACEUTICALS INC | Tablet | TADALAFIL 5 MG | Marketed |
| 02452243 | MAR-TADALAFIL | MARCAN PHARMACEUTICALS INC | Tablet | TADALAFIL 20 MG | Marketed |
| 02451689 | MINT-TADALAFIL | MINT PHARMACEUTICALS INC | Tablet | TADALAFIL 10 MG | Marketed |
| 02451670 | MINT-TADALAFIL | MINT PHARMACEUTICALS INC | Tablet | TADALAFIL 5 MG | Marketed |
| 02451697 | MINT-TADALAFIL | MINT PHARMACEUTICALS INC | Tablet | TADALAFIL 20 MG | Marketed |
| 02451662 | MINT-TADALAFIL | MINT PHARMACEUTICALS INC | Tablet | TADALAFIL 2.5 MG | Approved |
| 02410621 | MYLAN-TADALAFIL | MYLAN PHARMACEUTICALS ULC | Tablet | TADALAFIL 2.5 MG | Marketed |
| 02410648 | MYLAN-TADALAFIL | MYLAN PHARMACEUTICALS ULC | Tablet | TADALAFIL 5 MG | Marketed |
| 02410664 | MYLAN-TADALAFIL | MYLAN PHARMACEUTICALS ULC | Tablet | TADALAFIL 20 MG | Marketed |
| 02410656 | MYLAN-TADALAFIL | MYLAN PHARMACEUTICALS ULC | Tablet | TADALAFIL 10 MG | Marketed |
| 02452480 | NRA-TADALAFIL TABLETS | NORA PHARMA INC | Tablet | TADALAFIL 5 MG | Marketed |
| 02452499 | NRA-TADALAFIL TABLETS | NORA PHARMA INC | Tablet | TADALAFIL 10 MG | Marketed |
| 02409437 | PMS-TADALAFIL | PHARMASCIENCE INC | Tablet | TADALAFIL 10 MG | Marketed |
| 02409445 | PMS-TADALAFIL | PHARMASCIENCE INC | Tablet | TADALAFIL 20 MG | Marketed |
| 02409429 | PMS-TADALAFIL | PHARMASCIENCE INC | Tablet | TADALAFIL 5 MG | Marketed |
| 02409410 | PMS-TADALAFIL | PHARMASCIENCE INC | Tablet | TADALAFIL 2.5 MG | Marketed |
| 02441101 | TADALAFIL | TEVA CANADA LIMITED | Tablet | TADALAFIL 5 MG | Approved |
| 02441098 | TADALAFIL | TEVA CANADA LIMITED | Tablet | TADALAFIL 2.5 MG | Approved |
| 02441136 | TADALAFIL | TEVA CANADA LIMITED | Tablet | TADALAFIL 20 MG | Approved |
| 02441128 | TADALAFIL | TEVA CANADA LIMITED | Tablet | TADALAFIL 10 MG | Approved |
| 02452111 | TARO-TADALAFIL | SUN PHARMA CANADA INC | Tablet | TADALAFIL 20 MG | Marketed |
| 02452073 | TARO-TADALAFIL | SUN PHARMA CANADA INC | Tablet | TADALAFIL 5 MG | Marketed |
| 02440156 | TEVA-TADALAFIL | TEVA CANADA LIMITED | Tablet | TADALAFIL 5 MG | Marketed |
| 02440164 | TEVA-TADALAFIL | TEVA CANADA LIMITED | Tablet | TADALAFIL 10 MG | Marketed |
| 02440172 | TEVA-TADALAFIL | TEVA CANADA LIMITED | Tablet | TADALAFIL 20 MG | Marketed |
| 02440148 | TEVA-TADALAFIL | TEVA CANADA LIMITED | Tablet | TADALAFIL 2.5 MG | Marketed |
| 02428636 | ACT TADALAFIL | TEVA CANADA LIMITED | Tablet | TADALAFIL 5 MG | Cancelled Pre Market |
| 02428644 | ACT TADALAFIL | TEVA CANADA LIMITED | Tablet | TADALAFIL 10 MG | Cancelled Pre Market |
| 02428652 | ACT TADALAFIL | TEVA CANADA LIMITED | Tablet | TADALAFIL 20 MG | Cancelled Pre Market |
| 02338327 | ADCIRCA | ELI LILLY CANADA INC | Tablet | TADALAFIL 20 MG | Cancelled Post Market |
| 02437937 | DOM-TADALAFIL | DOMINION PHARMACAL | Tablet | TADALAFIL 20 MG | Cancelled Pre Market |
| 02437929 | DOM-TADALAFIL | DOMINION PHARMACAL | Tablet | TADALAFIL 10 MG | Cancelled Pre Market |
| 02437910 | DOM-TADALAFIL | DOMINION PHARMACAL | Tablet | TADALAFIL 5 MG | Cancelled Pre Market |
| 02437902 | DOM-TADALAFIL | DOMINION PHARMACAL | Tablet | TADALAFIL 2.5 MG | Cancelled Pre Market |
| 02451824 | JAMP-TADALAFIL | JAMP PHARMA CORPORATION | Tablet | TADALAFIL 2.5 MG | Dormant |
| 02452286 | MAR-TADALAFIL | MARCAN PHARMACEUTICALS INC | Tablet | TADALAFIL 2.5 MG | Dormant |
| 02452472 | NRA-TADALAFIL TABLETS | NORA PHARMA INC | Tablet | TADALAFIL 2.5 MG | Dormant |
| 02452081 | TARO-TADALAFIL | SUN PHARMA CANADA INC | Tablet | TADALAFIL 2.5 MG | Dormant |
| 02452103 | TARO-TADALAFIL | SUN PHARMA CANADA INC | Tablet | TADALAFIL 10 MG | Dormant |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 23341 | 2020-03-16 | Abbreviated New Drug Submission (ANDS) | Updated labelling materials Administrative: Merger/Buy-out |
| 18249 | 2016-07-12 | Abbreviated New Drug Submission (ANDS) |
International API supply for TADALAFIL
21 valid EDQM Certificates of Suitability from 21 holders. 27 active FDA Drug Master Files.
Request a quote for ACT TADALAFIL